Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG

Process Biochemistry

Volumn 42, Issue 12, 2007, Pages 1625-1631

  Li, Xing Qi ^a,b   Lei, Jian Du ^a   Su, Zhi Guo ^a   Ma, Guang Hui ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Branched mPEG; Half life time; Monopegylated rhG CSF; Relative bioavailability; rhG CSF; Synthesis

Indexed keywords

AMINO ACIDS; BIOACTIVITY; ELECTROPHORESIS; ESTERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

BRANCHED MPEG; HALF LIFE TIME; RELATIVE BIOAVAILABILITY; RHG-CSF;

POLYETHYLENE GLYCOLS;

EID: 36048934398     PISSN: 13595113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.procbio.2007.09.005     Document Type: Article

References (27)

1. Welte K., Gabrilove J., Bronchud M., Platzer E., and Morstyn G. Filgrastim (r-metHuG-CSF):The first 10 years. Blood 88 (1996) 1907-1929
2. Heussner P., Haase D., Kanz L., Fonatsch C., and Welte K. Freund M G-CSF in the long term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. Int J Hematol 62 4 (1995) 225-234
3. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2 (2003) 214-221
4. Molineux G. Pegylation: engineering inproved pharmaceuticals for enhanced therapy. Cancer Treat Rev Suppl. A (2002) 13-16
5. Roberts M.J., Bentley M.D., and Harris J.M. Chemistry for peptide and protein PEGylation. Adv Drug Delivery Rev 54 (2002) 459-476
6. Monfardini C., Schiavon O., Caliceti P., Morpurgo M., Harris J.M., and Veronese F.M. A branched monmethoxypoly(ethylene glycol) for protein modification. Bioconjugate Chem 6 (1995) 62-69
7. Reddy K.R., Modi M.W., and Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 54 (2002) 571-586
8. Foser S., Schacher A., Weyer K.A., Brugger D., Dietel E., Marti S., et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Exper Purif 30 (2003) 78-87
9. Kozluwski A., Charles S.A., and Harris J.M. Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs 15 (2001) 419-429
10. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., et al. Rational design of a potent long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjugate Chem 12 (2001) 195-202
11. Kinstler O.B., Brems D.N., Lauren S.L., Paige A.G., Hamburger J.B., and Treuheit M.J. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res 13 (1996) 996-1002
12. Guiotto A., Pozzobon M., Sanavio C., Schiavon O., Orsolini P., and Veronese F.M. An improved procedure for the synthesis of branched polyethylene glycols (PEGs) with the reporter dipeptide met-βala for protein conjugation. Bioorg Med Chem Lett 12 (2002) 177-180
13. Ren Y., Zhang H.T., and Huang J.L. Synthesis and cytotoxic activity of platinum complex immobilized by branched polyethylene glycol. Bioorg Med Chem Lett 15 (2005) 4479-4483
14. Souza L.M., Boone T.C., Gabrilove J., Lai P.H., Zsebo K.M., Murdock D.C., et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232 (1986) 61-65
15. Zailipsky S., Seltzar R., and Menon-Rudolph S. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. Biotechnol Appl Biochem 15 (1992) 100-114
16. Ma G.H., Gong F.L., Hu G.H., Hao D.X., Liu R., and Wang L.Y. Multi-scale structures and microsphere complex systems. China Particuology 3 (2005) 296-303
17. Li X.Q., Meng F.T., Ma G.H., and Su Z.G. A simple and efficient method for synthesis of carboxymethylated polyethyleneglycol. J Chem Res 5 (2005) 280-281
18. Lu Y.A., and Felix A.M. Pegylated peptides II: solid-phase synthesis of amino-carboxy- and side-chain pegylated peptides. Int J Peptide Protein Res 43 (1994) 127-138
19. Naoki S., Shigetaka A., and Satoru M. A new bioassay for human granulocyte colony stimulating factor (hG-CSF) using muring myeloblastic NFS-60 cells as targets and estimation of its levels in sera from normal health persons and patients with infections and hematological disorders. J Exp Hematol 17 (1989) 116-119
20. Ballon, Pascal, Sebastian. G-CSF conjugates. WO 00/44785. 2000.08.03.
21. Michael D.B., Michael J.R., and Harris J.M. Reductive amination using poly(ethylene glycol) acetaldehyde hydrate. Generated in situ: applications to chitosan and lysozyme. J Pharm Sci 87 (1998) 1446-1449
22. Jackson C.C., Carlto J.L., Kuzmincki K., Lang G.M., and Sehon A.H. Synthesis, isolation and characterization of conjugates of ovalbumin with and monomethoxy polyethylene glycol using cyanuric chloride as the coupling agent. Anal Biochem 165 (1987) 114-127
23. Sherman M.R., Williams L.D., Saifer M.G.P., French J.A., Kwak L.W., and Oppenheim J.J. Conjugation of high-molecular weight poly(ethylene glycol) to cytokines: granulocyte macrophage colony-stimulating factors as model substrates poly(ethylene glycol) chemistry and biological application. ACS Symp Ser 680 (1997) 155-169
24. Conan J.F., and James M.V.A. PEG-proteins: reaction engineering and separation issues. Chem Eng Sci 61 (2006) 924-939
25. Sins G.E.C., and Snape Y.J. A method for the estimation of polyethylene glycol in plasma protein fraction. Anal Biochem 107 (1980) 60-63
26. Maxfield J., and Shepherd W. Conformation of poly(ethylene oxide) in the solid state, melt and solution measured by Raman scattering. Polymer 10 (1975) 585-589
27. Glue P., Fang J.W.S., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., et al. The hepatitis C intervention therapy group. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics safety and preliminary efficacy data. Clin Pharmacol Ther 68 (2000) 556-567